Information Services banner Edinburgh Research Archive The University of Edinburgh crest

Edinburgh Research Archive >
Clinical Sciences, School of >
School of Clinical Sciences publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1842/4184

This item has been viewed 151 times in the last year. View Statistics

Files in This Item:

File Description SizeFormat
NormanJE_MetformicandWeightLoss.pdf1.12 MBAdobe PDFView/Open
Title: Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses
Authors: Harborne, L. R.
Sattar, N.
Norman, J. E.
Fleming, R.
Issue Date: Aug-2005
Journal Title: Journal of Clinical Endocrinology & Metabolism
Volume: 90
Issue: 8
Page Numbers: 4593-4598
Publisher: The Endocrine Society
Abstract: CONTEXT: Metformin treatment of women with polycystic ovary syndrome (PCOS) is widespread, as determined by studies with diverse patient populations. No comparative examination of weight changes or metabolite responses to different doses has been reported. OBJECTIVE: The aim of this study was to determine whether different doses of metformin (1500 or 2550 mg/d) would have different effects on body weight, circulating hormones, markers of inflammation, and lipid profiles. DESIGN: The study included prospective cohorts randomized to two doses of metformin. SETTING: The study was performed at a university teaching hospital with patients from gynecology/endocrinology clinics. PATIENTS: The patients studied were obese (body mass index, 30 to <37 kg/m2; n = 42) and morbidly obese (body mass index, > or =37 kg/m2; n = 41) women with PCOS. INTERVENTION: Patients were randomized to two doses of metformin, and parameters were assessed after 4 and 8 months. MAIN OUTCOME MEASURES: The main outcome measures were changes in body mass, circulating hormones, markers of inflammation, and lipid profiles. Results: Intention to treat analyses showed significant weight loss in both dose groups. Only the obese subgroup showed a dose relationship (1.5 and 3.6 kg in 1500- and 2550-mg groups, respectively; P = 0.04). The morbidly obese group showed similar reductions (3.9 and 3.8 kg) in both groups. Suppression of androstenedione was significant with both metformin doses, but there was no clear dose relationship. Generally, beneficial changes in lipid profiles were not related to dose. CONCLUSION: Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses. Additional studies are required to determine whether other aspects of the disorder may benefit from the higher dose of metformin.
URI: http://jcem.endojournals.org/cgi/content/abstract/90/8/4593
http://hdl.handle.net/1842/4184
ISSN: 0021-972X
Appears in Collections:School of Clinical Sciences publications

Items in ERA are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! Unless explicitly stated otherwise, all material is copyright © The University of Edinburgh 2013, and/or the original authors. Privacy and Cookies Policy